How does tapentadol’s dual mechanism of action (MOR agonism and NRI) differentiate it from traditional opioids like morphine or oxycodone in the management of cancer pain?

What were the main findings from the Japanese and European phase III randomized trials comparing tapentadol PR with oxycodone PR and morphine PR?

In nonrandomized retrospective studies from Japan, what discontinuation rates and adverse event profiles were observed for tapentadol online compared to other opioids?

What evidence supports tapentadol’s effectiveness in both opioid-naïve and opioid-tolerant cancer patients, and how quickly was pain relief achieved in these studies?

How do chronic noncancer pain studies (e.g., diabetic peripheral neuropathy, low back pain, osteoarthritis) contribute to understanding the long-term efficacy and tolerability of tapentadol?

Based on the collective evidence from randomized and nonrandomized trials, in what clinical scenarios might tapentadol be preferred over morphine or oxycodone?

Tapentadol has been available in Australia, Europe, and the United States for over 12 years and its clinical use continues to expand. The compound was developed through rational drug design to combine two mechanisms: μ-opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). Tapentadol is the first and currently the only representative of this MOR-NRI class.

Unlike conventional opioids such as morphine, fentanyl, or oxycodone, which act solely through MOR activation, buy tapentadol provides analgesia by both stimulating MOR and blocking norepinephrine reuptake. This dual mechanism inhibits pain transmission along ascending and descending pathways. MOR activation is most relevant for acute nociceptive pain, while the NRI component reduces central sensitization and helps prevent the transition from acute to chronic neuropathic pain.

In contrast to tramadol, tapentadol has no clinically meaningful serotonergic effect, resulting in more predictable analgesia across different clinical settings. It is available in both immediate-release and prolonged-release (PR) formulations. Its analgesic potency is approximately two to three times greater than tramadol, but lower than morphine and oxycodone. Because tapentadol undergoes hepatic glucuronidation rather than cytochrome P450 metabolism, it is less prone to drug–drug interactions and variability linked to CYP genetic polymorphisms.

Although its binding affinity to MOR is considerably lower than morphine, tapentadol provides effective pain relief due to the synergy between MOR activation and NRI. This mechanism also results in a reduced “μ-load,” meaning a lower relative contribution of opioid-related adverse effects such as respiratory depression, constipation, and endocrine disturbances compared with pure MOR agonists.

Cancer-related pain remains highly prevalent, with over 60% of patients with advanced disease reporting moderate to severe pain. Tapentadol has been studied in a wide range of oncology populations, including opioid-naïve patients, those previously treated with opioids, and patients experiencing nociceptive, neuropathic, or mixed pain associated with solid tumors, hematologic malignancies, or anticancer treatment.

To date, at least five randomized controlled phase III trials and multiple nonrandomized studies have evaluated tapentadol in cancer pain. Collectively, these studies support its efficacy and favorable safety profile, highlighting tapentadol as an effective therapeutic option for managing cancer-related pain.

There are currently five randomized controlled phase III trials investigating tapentadol in patients with cancer pain, along with several nonrandomized studies. The randomized studies are summarized first, followed by recent nonrandomized trials and long-term data from noncancer pain populations.

Previous systematic reviews, including a Cochrane review, identified four RCTs with more than 1,000 adults suffering from moderate to severe cancer pain. These trials compared tapentadol with morphine, oxycodone, and placebo. A more recent RCT (n = 114) evaluated tapentadol versus tapentadol combined with duloxetine in chemotherapy-induced peripheral neuropathy (CIPN). Due to methodological heterogeneity, data pooling was not possible. Most of the studies were small to medium in size but were generally considered to carry a low or uncertain risk of bias. One trial was open-label, and another was terminated early because of issues with rescue medication, leaving it underpowered and unpublished. Except for the most recent unfunded study, all others were industry-sponsored.

Across the trials, tapentadol consistently provided pain relief comparable to morphine and oxycodone. Most were designed as noninferiority studies. Tapentadol demonstrated similar overall tolerability but was associated with less constipation compared with other opioids.

Two key multicenter, double-blind, active-controlled phase III studies assessed prolonged-release (PR) tapentadol in moderate to severe cancer pain: one conducted in Japan and Korea, and one in Europe. In the Asian trial, tapentadol PR was at least as effective as oxycodone PR, with significant reductions in pain intensity and fewer cases of constipation. In the European study, tapentadol PR was superior to placebo and comparable to morphine PR in terms of response rate, while showing improved gastrointestinal tolerability. A post-hoc subgroup analysis confirmed that patients dissatisfied with prior tramadol therapy could be safely converted to tapentadol, with around 70% reporting pain reduction.

A Japanese open-label phase III trial with 100 patients demonstrated that conversion from strong opioids to tapentadol PR was both effective and well tolerated, with fewer gastrointestinal side effects compared with morphine.

The most recent RCT involved 114 patients with CIPN randomized to receive either tapentadol or tapentadol plus duloxetine for 28 days. Both groups showed significant reductions in pain and improvements in quality of life measures, with no difference in adverse events between the two arms. The study confirmed the noninferiority of tapentadol monotherapy, although interpretation was limited by the absence of a duloxetine-only or placebo group.

In summary, five phase III RCTs have assessed tapentadol in adults with moderate to severe cancer pain, comparing it with placebo, morphine, oxycodone, and tapentadol plus duloxetine. Results consistently show that tapentadol is at least as effective as morphine and oxycodone, more effective than placebo, and associated with fewer gastrointestinal adverse effects.

Beyond RCTs, several nonrandomized investigations have evaluated tapentadol in cancer pain. One prospective open-label multicenter trial in Korea included 650 patients, of whom 349 had moderate to severe chronic cancer pain. After four weeks, tapentadol reduced pain scores by an average of 2.1 points on the 11-point NRS, and this effect was sustained over six months. More than 90% of patients reported meaningful improvement in pain, confirming statistically significant benefits.

A small prospective open-label Italian study evaluated tapentadol in 31 patients with chemotherapy-induced peripheral neuropathy (CIPN). Within the first week, seven patients (23%) discontinued due to nonserious adverse events, and one withdrew. After three months, 19 of 22 patients (86%) reported meaningful analgesic benefit (≥30% reduction in pain intensity), with 68% achieving ≥50% reduction. Tapentadol significantly decreased both NRS and DN4 scores (P < 0.001) and improved global health status (P = 0.046).

A retrospective comparative study from Japan assessed 127 cancer patients with neuropathic pain treated with tapentadol (n = 29), methadone, oxycodone, fentanyl, or hydromorphone. Tapentadol showed significantly greater pain reduction compared with oxycodone at all timepoints (day 7, P = 0.0024) and demonstrated a nonsignificant trend toward superiority over methadone, fentanyl, and hydromorphone. Discontinuation rates were lowest in the tapentadol group (0%) compared with the other opioids (3.8–10%).

Another retrospective single-center Japanese study of 84 patients with moderate to severe cancer pain found that 93% achieved ≥50% reduction in NRS scores. Median pain intensity decreased from 7 at baseline to 2 after initial relief, and further to 1 at the end of maintenance (P < 0.0001). Both opioid-naïve and opioid-tolerant patients experienced significant benefit, typically within three days. Nausea resolved in nearly half of affected patients, with no discontinuations due to serious adverse events.

In a large retrospective multicenter study of 906 Japanese cancer patients, 17% discontinued tapentadol due to adverse events, most commonly nausea (5%), drowsiness (2%), delirium, or cardiovascular symptoms (1%). The majority of discontinuations occurred within 28 days of treatment initiation. Another single-center retrospective study of 175 patients reported that tapentadol was often initiated by palliative care teams, particularly for patients with neuropathic pain or a history of nausea; discontinuation due to adverse events occurred in 8%.

Overall, recent prospective and retrospective studies consistently support tapentadol as a safe and effective treatment for cancer pain, though limitations such as retrospective design and lack of controls require cautious interpretation.

Chronic noncancer pain studies
Evidence from systematic reviews and observational studies confirms tapentadol’s role beyond cancer pain. A systematic review of neuropathic pain found tapentadol effective in diabetic peripheral neuropathy and chronic low back pain. A network meta-analysis indicated lower rates of nausea and constipation compared with other strong opioids. In a Spanish multicenter, open-label 72-week extension study of 81 patients with severe osteoarthritis or low back pain, analgesia and quality of life improvements were maintained, with stable dosing and high patient satisfaction. Tapentadol-related adverse events occurred in 18%, most commonly constipation (7%).

Additional observational studies comparing tapentadol with opioids such as fentanyl, morphine, buprenorphine, and oxycodone demonstrated superior pain relief and tolerability for tapentadol. A 12-week German database analysis of 2,331 patients with chronic low back pain reported higher responder rates and better safety for tapentadol prolonged release (P < 0.001).

Conclusion
Tapentadol, a dual MOR agonist and NRI, has been extensively investigated across cancer and noncancer pain populations. Phase III randomized trials confirm its noninferior efficacy compared to morphine and oxycodone, with fewer gastrointestinal side effects. Recent nonrandomized studies further support its safety and effectiveness, while long-term data in chronic noncancer pain suggest sustained analgesia without evidence of tolerance for up to two years. Tapentadol should be considered a valuable alternative to morphine or oxycodone, particularly when gastrointestinal toxicity, intolerance to conventional opioids, or the need for long-term therapy are clinical concerns.